Oric Pharmaceuticals, Inc. Jefferies Global Healthcare Conference in London - ORIC PHARMACEUTICALS INC
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Jacob Chakot, CEO, and Dominic Piscitelli, the CFO, from OREC. And we're going to do fireside chat format, so maybe for those who are new to the story, if you guys want to give a one-minute intro to the company. Sure. Thanks for having us, Maury. So ORECs stands for Overcoming Resistance in Cancer, which in a nutshell is the mission of the company, We have two late-stage programs, so one of them is called Rinzimetastat, which is an oral PRC2 inhibitor that's being developed in prostate cancer that just entered a Phase III study. Himalaya's one a couple months ago. And then the other program is Enozertinib, which is another oral program. That one is targeted at lung cancer, two different populations within lung cancer that are targeted therapy populations, so EGFR atypical mutations and then EGFRExon20. That one, we've announced intentions to start a phase three next year in 2027. So they're both, like I said, late-stage programs. Both had data updates within the last month, so a lot to talk about today. And the company is super well-funded, which Dominic can talk about later. Yeah, yeah, it's a great intro. And, yeah. You've had two data updates recently. So let's start off with Renzi for prostate cancer. Maybe talk about how Renzi and Mevro, which is Pfizer's drug, how those drugs differentiate in terms of target and pharmacology and how that translates to their clinical profiles and what might be similar or different. Yeah, so it's a good lesson in Drug Development 101, Maury, as you compare the Rinzimetastat R drug to Mevrometastat, which is Pfizer's drug that is now in three different Phase III trials within prostate cancer. So both are going after the same target complex, which is called PRC2. It's an epigenetic modifier that for years has been, And folks have been trying to drug that in prostate cancer in combination with an AR inhibitor, an androgen receptor inhibitor. Which is really the big 8,000-pound gorilla in the space. So that's enzalutamide, apalutemide, and darolutamide. People are trying to figure out a way to make those drugs work even better. And so the target's the same. Now, there's different subunits of the PRC2 complex. Pfizer targets the EZH2 subunit, which is the catalytic subunIT. We target the EED subunIt. So it's more of an allosteric inhibition of the PRC2 complex. But the point is it's the same biological target in terms of mechanism of action and activity. What is quite different, obviously, is the drug properties, which is that Pfizer seems to have solved a lot of the issues of drug properties that kind of plagued the first-generation PRC-2 inhibitors, which had one- or two-hour half-life CYP autoinduction, meaning those drugs would rev up the CYPs enzymes. They were also metabolized by the CYNPs enzymes, So you would get very funky dynamics like dose-dependent decreases in exposure. The more drug you give, the less exposure you get. So that's why those were imperfect clinical experiments for the first-gen inhibitors. Pfizer appears to have about a four-hour half-life and does not seem to have CYP autoinduction. So they seem, by giving high doses, to be able to get to the right exposures. But our drug has a much longer half-Life, a 20-hour Half-Life in fact. and then because we're dosing with darolutamide which itself is not a sip inducer it means that we can give a fraction of the of the dose they give and so ultimately pfizer is giving close to 1.8 grams of drug per day in their phase 3 trials that's their phase three dose whereas ours is 400 milligrams once a day so it's a fractionof the dose ultimately where that ought to shake out is a lower c max for our drug and that should translate into a better safety profile so you should still see the same on-target tox for the two programs, which would be GI tox and heme tox. You just see a lot less of it and a lot lower severity of it for us with rinzimetastat in combination with darolutamide than what Pfizer has seen with theirs. And I think at this point, there's ample data that has shown that the efficacy of the two drugs is extremely similar and where it is extremely different is the safety. Got it. Yeah, good compare and contrast between the two programs. And earlier this week, as part of your second half program update for REN-Z, you provided an update for both the post-Aviadarone and post-AR inhibitor cohorts. What are the key takeaways from this update? Yeah, so if you take a big step back to March of this year, we provided the first look at the dose optimization data for Ren-Z metastat in combination with darolutamide in those two populations you mentioned. So post-Abiraterone castration-resistant prostate cancer and then post-Ar inhibitor castration resistant prostate cancer. The reason that those two subgroups matter is if you just take a big, big step back, you will be hard-pressed today to find a patient with prostate cancer who has not received one of this class of drugs called ARPIs, so androgen receptor pathway inhibitors. Half of the scripts of the ARPIS is abiraterone. The other half is one of the three big AR inhibitors, which are obviously all still branded today. And so those are the two populations that we're studying, that's two populations Pfizer has studied historically. What you saw from us in the March update, which was quite early at the time, was early landmark PFS. So at that time, three month, four month, and five month landmark PFFs that were right on top of Pfizer's PFF in the equivalent populations and a safety profile that was much better, I think demonstrably better, along the lines of what I mentioned earlier, which is less GI tox, less heme tox, so less of the on-target talks that you'd expect. In the five and a half intervening months since we did that update, we took another look at the data. The durability is continuing to hold up quite nicely, so now as you look at even longer landmark PFS, so eight-month, nine-months, ten-month landmark PFS. Again, the rates are right on top of Pfizer, so both drugs are kind of in that 60 percent ten- month landmark PFC range in each of those two populations, which is demonstrably higher than any of the standards of care that are available to those patients today. And then the safety continues to hold up, which is almost all grade 1 AEs, so a much cleaner safety profile. Very little in the way of worse than that. And so I think it's looking quite good. And as you think about just taking a big step back and just look at the actual durability, at the time of the March update, there was 15 patients who were continuing ongoing on the study without progression. And at the latest data cut, so five and a half months later, almost all of those patients were still ongoing without progression. There was only three progressions out of the 15 in the last five and half months. That's remarkable in that population. And so what it tells us is that in the post-abiraterone population, which is where Pfizer's first phase 3 study is, it's where our most recently initiated phase 3 studies is, that the data is holding up quite well in terms of efficacy and the safety profile. and also tells us what may be a future Phase III study, which is a post-AR inhibitor population, it's also holding up quite well. Got it. Yeah, so seeing that durability and seeing the updated safety, I think, was a question that a lot of people had, and so it's nice having that out in the public domain. And for that data set, which aspect do you view as more informative for de-risking your Phase III Himalayas I trial? Is it the durability in the post-ABI cohort, activity in the post-AR inhibitor patients or safety dose intensity over a longer follow-up? I think it's probably all of the above. I mean, at this point, when you look at early phase one data sets, I mean you're trying to see as much as you can to de-risk the future phase three studies. I think It's quite helpful that we have seen this signal not only, because at the end of the day, you know, call a spade a spate. It's still uncontrolled data sets not randomized data sets. So the more data the better. So it's helpful that We're seeing that positive signal across two different data sets. I think in particular, the post-AR inhibitor data set is particularly inspiring just from the point of view that an AR inhibitor alone, so AR inhibidor dosed after AR inhibitor is just not a thing. It doesn't work. Everybody knows that. You'd get about two months of PFS in those patients. So the fact that out at 10 months, it's a 60% landmark PFS should really be conviction strengthening in terms of the mechanism of action, the ability for this to really add significantly on top of AR inhibitor monotherapy alone. And then, like I said, the toxicity profile continues to look just as good, just as clean as it did back from the March update. So I think all of it is quite helpful. Got it. And Pfizer now expects MevPro1 top line in first quarter of next year. Given that this is an events-driven trial, what do you think the timing shift most likely tells us? Could it reflect slower events on MevRo, stronger control on performance, censoring dropout or the enrollment curve or just uh processing the the data well first of all i applaud you for waiting until the fourth question of the fireside to ask us about pfizer and mevpro one uh it could be any of the above i guess is the reality i think i think um in general the way people have looked at that data set and pfizers communication around that data Set has been that i think it's pretty well understood how the control arm should perform in mev pro one so to remind folks the control arm is a physician's choice of either AR switch, so the patient would get enzalutamide in that case, or chemotherapy. The physician can choose. I think one of the big questions there is, well, you understand exactly how enzulutamate should perform in that population, which is roughly five to six months of PFS. You understand exactly How chemo should perform in that Population, which is Roughly seven to eight months of pfs one of the outstanding questions is what is the actual mix of of the physician's choice control arm and ends up versus chemo i think pfizer's assumption in the protocol our assumption in our protocol is roughly a 50 50 mix it sounds like pfizzer has has commented in smaller group discussions over the past month saying that if anything they are seeing a site slight skew towards ar switch rather than chemotherapy if anything that would be a good thing in terms of where you think that control arm is going to settle out. Chemotherapy obviously would do a little bit better than, than enzomonotherapy. So if they're seeing a little bit more enzimonotherapy, that means the control arm likely is not doing something, you know, super surprising in terms of long performance. And so if you know how the controlarm is going to do, then the fact that the trial is taking longer to read out in general should mean that the treatment arm is doing quite well because you're not seeing the events on the treatment arm. So that's statistically the most likely scenario. There's obviously corner case scenarios, which would be related to toxicity or some other reason. If there's a high censoring rate, maybe that's why it's taking longer for events to read out. So I don't know. Ultimately, Pfizer is the owner of the data, and we'll find out in Q1 next year what the final result is. I just think at this point, there is so much data from Pfizer and from us at OREC in different populations within CRPC across different data sets, all of which has pointed to a pretty profound synergy of an AR inhibitor in combo with a PRC2 inhibitor. I think statistically speaking, you can almost certainly rule out a big miss from Pfizer at this point. But I think, I suppose, a small miss might still be on the table. And obviously, there could be reasons for that. Got it. And yeah, maybe talk more about the range of outcomes that we could get from mepro1 and how you define success in their phase three and what are the read-throughs for renzi in each of these scenarios sure i mean so just being simple about the phase three readout for any program uh you know my caveman analysis would say that you could have a big win you could have a small win you Could have a bare miss or you could Have a big miss um i think like i said statistically speaking the chances for a big Miss at this point i think are close to zero just given you know where we are in in the timelines of mepro1 uh and whatnot and just as you do the stats analysis so if it's a near miss there's still reasons where you could have a near mess and i kind of alluded to some of those earlier which would be in in one case if um i've already talked about the toxicity profile that they've seen uh if if tox ends up being an issue that leads to you know censoring events and maybe that's why there's a delay in trial separately if toxicity leads to dose reductions, and therefore they have a lower therapeutic intensity that could compromise their therapeutic benefit. You have to keep in mind they have very big food effect, so they're dosing 875 milligrams twice a day in a fed regimen, which they have said that based on food effect cohorts is the same exposure as they get with 1,250 milligrams twice a days in a fasted regimen. That's obviously a big difference in dose. That means they have a big food effect. Now, the food effect cohort data that they showed at ASCO of 2025 suggests that they get the same exposure with those two doses. But keep in mind, a food effect court in a couple dozen patients, you can roughly manage what those patients are eating. In a global phase three study with 600 patients, your diet's different than my diet, and that food effect, you know, it may not be exactly exposure matched. So there's some variability there that interjects. interjects. I mentioned earlier that they have a big DDI with enzalutamide because enzulutamate is a SIP inducer. You can always overcome those kind of DDIs by dosing higher, and that's obviously what they're trying to do. But your SIP enzymes are different than my SIP Enzymes. And so that also introduces some level of variability. So my point is that there's little reasons here and there on the edges that could explain a near miss that they might have. Any of those reasons don't read through to rinzimetastat because rinzemetastat, our drug, does not have a significant food effect. We're dosing with darolutamide, which is not a SIP inducer. Obviously, you've seen our toxicity profile is very clean. So there's not a lot of read-through from any of those near-miss scenarios to OREC. The one thing that was a bit out of our control was what is the physician's choice control arm composition going to look like, which again, Pfizer seems to be indicating that it's more AR switch than chemotherapy. Even to control that scenario, In our protocol, we inserted a cap of 60% in the physician's choice control arm, meaning that no more than 60% of the physician'S choice control arm could be AR switch or chemotherapy, for that matter. We didn't want imbalance in either direction. But given Pfizer's commentary, it seems like that's not going to be an issue anyway. But my point being, Maury, that all of these near-miss scenarios, we have tried to control as much as possible for limiting the read-through to rinzimetastat and darolutamide, our combination. And then obviously the upside scenario, so a small win or even a bigger win, have implications of how we think about what the next trial might be. And so in other words, if the signal looks anywhere close to as strong as what they had out of their randomized phase 2 data, I would say that this mechanism is going to be game-changing in the prostate space. And if that's the case, and then depending on what we see from their final toxicity profile, A lot of that might urge us to go, you know, faster, quicker into the earlier line settings like castration-sensitive prostate cancer where MevPro3 is being conducted. And then keep in mind, on top of the top-line read from Mevpro1 next year and the detailed read from mevpro2 next year, they've also promised a top- line read from MEVPro2 next years. So all of those things together, I think, are going to heavily inform how we think about the right next step for our own program beyond Himalayas 1. Yeah, it makes a lot of sense, and went into a lot of detail there as well, which is helpful. I guess, is there more you could say on what would constitute a near miss? There's debate on hazard ratio, and is it near miss on statistical analysis, or on SAT-SIG, or is it on the hazard ratio number? I guess I'll just wait to see what the data show. I don't know. When I'm saying near miss, I mean, you know, if the trial doesn't hit, I guess it could be either of the explanations that you mentioned. But, look, I would also categorize as a near miss, I mean, even if it hits on stats, but it's just a hazard ratio that doesn't really get anybody excited. I mean those are also kind of in the camp of near miss. Yeah, but ultimately that should have some positive read-through to you guys based on those differentiation aspects. Yeah, clearly with that we think there's a lot of differentiation and a lot OF reasons why a near-miss would not read-thru directly to us. And so let's talk more about your Phase 3 study. So you started it in July. Can you remind us of the study design? And you previously assumed it would take about 16 months of enrollment and you'd get to top line in first half 28. Where are you today on site activation and enrollment relative to the plan? Yeah, so, you know, we aren't providing kind of intra-study updates on some of those operational milestones. But what I'd say is we started Himalayas 1 a couple months ago. It's in the early part of that hockey stick phase of Phase 3 trials. It's very much in the site activation and country activation stage of Phase 4. design. The design itself is extremely similar to Pfizer's design. That was by intention of making them as comparable to one another as possible, because we feel so strongly in the differentiation of RINCY that we wanted the two trials to be, you know, be able to put side by side to see kind of, you know at the end of the day, once they both read out, you which drug looks best. And so it's a 600 patient study, just like Pfizer's study. It's powered for the same thing, which is a 0.66 hazard ratio, 95% powered for a 0 .66 hazard ratio. So you could argue overpowered in that sense, but it means that you ought to get your readout quicker. It's a sole primary endpoint of radiographic PFS. There's no OS in the primary endpoint. You just have to have non-detriment on OS. You'll just want to see a trend in OS, which is exactly in line with all the recent phase 3s in prostate. And that's it. There's probably not much else. In terms of inclusion-exclusion criteria, it's the same population as MEVPRO-1, which is patients who are post-aboratorone, could have had up to one prior line of chemotherapy. No other prior therapies would have been allowed. In that sense, it is actually a slightly, quote-unquote, easier population than what we have thus far been showing. So Pfizer, that is exactly what Pfizer has done so far, is post-Aboradarone up to one prior line of chemotherapy in the phase one and phase two data they showed us. Of course, with us, you know, coming a little later to the game, we were more permissive, and we allowed a lot of other things into our study. So when I quote that our landmark PFS is right on top of theirs, keep in mind it's with a more pretreated population than theirs, that won't be the case. Once we get to the phase three, we'll make it as like-for-like as possible. Got it. Makes sense. And I want to talk about some of the competition in the space. So with J&J 6143 RIPTAC data, it showed interesting early PSA 50 and complete ORR and heavily pre-treated prostate cancer patients. What are your thoughts on the data, and what specifically does Mevro or Renzi need to show to remain differentiated? Yeah, so I see one of my friends from J&G in the audience, so i would say the same thing with or without him here in the audience, which is it was great data from the HALDA program that they presented. The PSA 50s, the PSA 90s were quite high in a very, very late stage prostate population. So kudos to them for being able to show that. What I would say that remains to be seen there is you just need more follow-up. You need to understand what the durability is for those patients. You need to know what the safety profile is for them. You know, if you go back and if you look at the swimmer plot that they showed there is no annotation for radiographic progression which is something you would typically look to see on a swimmer pot so i can't comment on literally just can't coment on what the durability is thus far that they're seeing maybe it's because it was early on that they didn't annotate that yet but i think that's an important piece that we're going to want to see to understand the durability of that program you also do see some liver talks you see some kidney talks in the profile that they presented again without the pk curves which they didn't include in the presentation but you see if you go back to the triple conference presentation from a year ago you can see that the pk curve should show you flat pk after 50 milligrams which is the go forward dose and where you see a lot of the talks in the recent data set is at a higher dose than the 50 megs but it's at a dose that has the exact same exposure as 50 milligrams so i my point is you just need more time to understand what the actual profile of that program is both on the durability side and the safety side but at the end of the day it's great data uh we we need to see those those aspects if it looks good once you get the full picture on durability and safety we might look to combine with a rip tech i mean with with their program it's a you know there's no reason why you wouldn't combine the two obviously mechanistically they can't combine with an ar inhibitor because they both bind at the ligand binding domain so they either have to come after an AR inhibitor or before an AR inhibitor, but not with an AR inhibitor which is the dosing that we're doing. But if that proves to be the next best AR inhibiter or version of an AR inhibitor then we might look to try to combine with them. Yeah, makes sense. And can you walk us through the commercial opportunities and dynamics if both Mevro and Renzi ultimately reach the market and what factors do you believe will drive physician choice between the two agents? Yeah, so the two patient populations that we are currently studying is a post-Everettarone which we're We're estimating about 17,000 patients in the U.S. That itself is about a $3.5 billion total adjustable market in the U.s. alone. XUS is pretty close to that as well. And the second is the post-AR inhibitor. That as well is about 20,000 people. That's about 20 thousand patients. So that's another $3 and a half billion opportunity in the U. S. Alone. So those are the two opportunities. Obviously the holy grail in prostate cancer is moving into early lines of the CSBC setting. There you talk about a 10 billion dollar opportunity. So that is kind of the overall opportunity there. This is prostate cancer. It's one of the largest opportunities in the space, obviously. And then from a differentiation standpoint, I think Jacob touched upon it. I mean, here, what we've shown today, both preclinically and clinically, we've showed basically the same on the efficacy front. If we continue to show the differentiation on the safety side, I think that's where the key differentiation really comes out. And the perfect analogy for this is in the AR inhibitor space. I was at Medivation, I know, and Zolidamide well. But, you know, Avaludamide came six years later, and that's doing $4 billion a year. and then a year after that came darolutamide, and that's where you kind of see a differentiated profile just on safety. The efficacy of the 3R inhibitors are basically the same, and it's only the differentiation on the safety, and they're really growing the fastest at this point in time. Yeah, good points on that. And so let's shift gears. We'll talk about inazertinib. You had data at ESMO recently. Maybe talk about how differentiated inazetinib CNS activity is relative to other EGFR-targeted therapies and why is CNS activity so important for these patients? Yes, happy to do that in two minutes or less. So inozertinib is a profoundly CNS-penetrant drug, and the reason that matters is a lot of our team came from Ignita prior to OREC, and at Ignita we developed a drug that was brain-penetrant in one of these targeted therapy targets within lung. And back then there was a debate about whether you wanted a drug to be CNS penetrant or not because there was concerns that you might have tox from that. It was unknown. Now it is dogma in the space, in the lung space, that you want the drug to be brain penetrant. And the whole reason for that is so many patients at initial presentation, even in the front line, 35% of patients present with CNS metastases. The first site of progression is often in the brain for drugs that are not brain penetrating. When you look at ALK, ROS, classical EGFR, all these different targets in targeted therapy, where the best-in-class profile has emerged, it is every single time, without exception, a brain penetrent drug. and you get longer durability with the brain-penetrant drug because you don't have patients progressing in the brain so fast. I would urge folks to look at the subgroup analyses for any of these drugs that are non-brain-penetrant versus brain-penetrant, and what you'll see is a dramatically different PFS and hazard ratio in the patients with versus without brain metastases that comes out in those data sets. And so, you know, a year ago, Maury, when we were talking about inazertinib, the worry I had is I knew that we were over-enrolling, so to speak, patients into the study with brain metastases, not by any intention of our own, but physicians knew the drug is so brain penetrant. What we ended up with in the data we presented at ESMO a month ago was that two-thirds of our patients in that data set had brain metástases at initial presentation. Close to half of the patients in the whole data set Had no prior treatment for brain metlastases before coming onto the study. And so I was worried that with that harder population, were our numbers going to look worse than the competition? As it turns out, Even with that hard population, where the competition is kind of topped out in the mid-60s on response rate, we had an 84% response rate. 70% intracranial response rate So the drug is looking phenomenally good in that population. Got it. And besides the response rate What else do you want to see on durability and DOR, PFS that would give you confidence that this is best in class? Yeah, obviously we want to See more durability And that'll be important But we're not waiting for that to start the first phase 3 study So the first phase 3 study, Redwood 1, is planned to start next year. Obviously, with the kind of response rates we've seen, with the intracranial activity we've seen, with the safety profile we've seen, a landmark PFS rate, which is what we can quote at this point, six-month landmark Pفس rate of 88%. Everything suggests that the drug is going to have great durability. We think it's incumbent for us to get this drug developed as quickly as possible and get it to patients as quickly as possible. So we're not waiting to read out durability from a phase one study. Got it. And maybe talk about the competitive landscape. You've got Aravant, J&J, and Black Diamond. How do you guys compare on efficacy and safety? Yeah. So I think the main issue, as you look at the competitive space, this applies for EGFR atypicals. Same thing applies for EGF-R exon 20, is that you have drugs that have one of two issues. Either it's a toxicity issue of just seeing too much of the EGfr wild type related toxicity, or even off-target toxicity. So from a lot of those drugs, you'll see things like liver enzyme elevations. You'll see anemia. And so you'll say QTC prolongation. Those are problems from the safety side of things. And or you see a lack of CNS activity. So that's the issue with all the drugs that you've talked about in terms of the competitive landscape is one or the other of those issues. And like I said, with inozertinib, we think that we've got a best-in-class profile at this point. Got it. So we're out of time, maybe in closing out, if you want to highlight the cash position and where the runway gets you. Yeah, Dom can quantify what I meant by super strong cash position. So we were well capitalized. We ended the third quarter with $345 million in cash investments. That does give us cash runway to the second half of 2028. That's a fully burdened number. What I mean by that is that obviously assumes the cost for the Himalayas One study, which is ongoing, and that does assume a Phase III study for Redwood One, which would be the Zeratum study and the atypical. goal. The key thing here is that our runway takes us in the second half of 2028, which is past our expected top-line data readout for the Himalayan One study. Jacob, Dominic, thanks so much for joining us today. Thank you, Maury. Thanks, Maura.
- Company
- ORIC PHARMACEUTICALS INC
- Keywords
- ORIC PHARMACEUTICALS INC